TIVC — Tivic Health Systems, Inc.

Summary of TIVC Q3 2025 Earnings Call

1. Key Financial Results and Metrics

• Revenue: Q3 revenue was $140,000, up from $126,000 in Q3 2024. However, year-to-date revenue decreased to $302,000 from $600,000 in the prior year.
• Cost of Sales: Increased to $291,000 from $82,000 in Q3 2024, primarily due to a $230,000 reserve for excess and obsolete inventory.
• Gross Margins: Excluding the inventory reserve, gross margins were 42% in Q3 compared to 35% in Q3 2024.
• Operating Expenses: Rose to $2.3 million in Q3 from $1.5 million in the prior year, driven by increased R&D investments and corporate costs.
• Net Loss: Increased to $2.6 million for Q3 2025 compared to $1.4 million in Q3 2024; year-to-date net loss was $6 million versus $4.2 million in 2024.
• Cash Position: Cash and cash equivalents totaled $3.5 million as of September 30, 2025, up from $2 million at the end of 2024.

2. Strategic Updates and Business Highlights

• Tivic Health is undergoing a strategic transformation, moving from bioelectronics to biologic pharmaceuticals, focusing on immune system-related therapies.
• The company has licensed entolimod and entelasta, targeting applications in acute radiation syndrome (ARS) and neutropenia.
• Progress includes successful verification of entolimod's cell line and the transfer of INDs to Tivic for ARS and advanced cancer.
• The VNS program has yielded new findings that may influence future commercial strategies, emphasizing personalized treatment parameters.

3. Forward Guidance and Outlook

• Tivic aims to advance entolimod through clinical trials, with expectations to enter Phase II studies for neutropenia and lymphocyte exhaustion.
• The company is focused on building relationships with military and government stakeholders for potential stockpiling of entolimod.
• Management expressed confidence in achieving GMP manufacturing validation for entolimod, which is seen as a critical milestone.

4. Bad News, Challenges, or Points of Concern

• The exit from the consumer health market resulted in inventory reserves and asset write-offs, indicating challenges in transitioning business focus.
• The contract manufacturer faced financial stress, causing delays in production schedules for entolimod.
• Increased operating expenses reflect the costs associated with the strategic shift, which may pressure short-term financial performance.
• The decline in year-to-date revenue suggests ongoing challenges in the transition away from consumer products.

5. Notable Q&A Insights

• Management emphasized the importance of the upcoming TechWatch meeting with BARDA to discuss entolimod's potential as a military countermeasure.
• There was a recognition of the need to reassess the commercial focus of the VNS program based on new findings, indicating flexibility in strategy.
• The call highlighted the company's commitment to advancing its biologics pipeline while managing the challenges of exiting the consumer market.

Overall, while Tivic Health Systems is making significant strides in its transformation and pipeline development, it faces challenges related to its strategic shift and operational execution that may impact near-term performance.